{"id":39777,"date":"2025-11-27T12:00:00","date_gmt":"2025-11-27T05:00:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=39777"},"modified":"2025-11-27T12:00:00","modified_gmt":"2025-11-27T05:00:00","slug":"gc-genome-publishes-blood-based-colorectal-cancer-screening-study-in-the-american-journal-of-gastroenterology","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=39777","title":{"rendered":"GC Genome Publishes Blood-Based Colorectal Cancer Screening Study in the American Journal of Gastroenterology"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2833373\/GC_Genome_logo_final_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\">YONGIN, <span class=\"xn-location\">South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 27, 2025<\/span><\/span> \/PRNewswire\/ &#8212; GC Genome, a leading clinical genomics and liquid biopsy company, announced that its collaborative study with Professor Byeon, Jeong-Sik&#8217;s team at Asan Medical Center has been published in <i>The American Journal of Gastroenterology(AJG)<\/i>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>GC Genome applied its proprietary AI-based fragmentomics technology, used in its MCED test, ai-CANCERCH. This study demonstrates the potential for a convenient, alternative to colonoscopy and fecal based screening methods, while enabling early detection of colorectal cancer and advanced adenomas.<\/p>\n<p><b>Study Overview<\/b><\/p>\n<ul type=\"disc\">\n<li>A total of 1,677 individuals were enrolled, including: 302 with\u00a0CRC, 108 with AA<\/li>\n<li>1,267 with normal\u00a0colonoscopy as healthy or non-cancer controls<\/li>\n<\/ul>\n<p>The test analyzes cfDNA fragmentomic signatures using low-coverage whole-genome sequencing (Lc-WGS) combined with a proprietary AI algorithm, enabling highly sensitive detection of early-stage disease.<\/p>\n<p><b>Key Findings<\/b><\/p>\n<ul type=\"disc\">\n<li>CRC sensitivity: 90.4%<\/li>\n<li>Specificity in individuals with normal\u00a0colonoscopy: 94.7%<\/li>\n<li>Sensitivities by\u00a0CRC stage : 84.2% (stage I), 85.0% (stage II), 94.4% (stage III), and 100.0% (stage IV)<\/li>\n<li>Sensitivity for T1N0 lesions (eligible for\u00a0endoscopic resection): 90.0%<\/li>\n<li>Sensitivity for AA: 58.3%<\/li>\n<\/ul>\n<p>The results remained consistent regardless of: CRC locations (left vs. right colon), age of CRC patients(&lt;60 vs. \u226560), and AA locations<\/p>\n<p>These findings highlight the test&#8217;s potential as a reliable cfDNA-based blood test for CRC screening and early prevention.<\/p>\n<p>A GC Genome spokes person stated &#8220;Detecting colorectal cancer together with precancerous lesions represents a meaningful advance in prevention. With our fragmentomics technology now validated through publication in a leading gastroenterology journal, GC Genome will continue expanding global clinical collaborations and screening applications.&#8221;<\/p>\n<p><b>About ai-CANCERCH<\/b><\/p>\n<p>Launched in <span class=\"xn-chron\">September 2023<\/span>, ai-CANCERCH is an AI-based multi-cancer early detection(MCED) test powered by Lc-WGS. Using just 10 mL of blood, the test detects signals associated with multiple cancers. A major upgrade\u2014expanding from 6 detectable cancers to 10 cancers (colorectal, lung, esophageal, liver, ovarian, pancreatic, biliary, breast, gastric, and head-and-neck)\u2014is planned for <span class=\"xn-chron\">January 2026<\/span>.<\/p>\n<p><b>About GC Genome<\/b><\/p>\n<p>GC Genome is a leading diagnostics company that aims to connect the care and cure to the world by offering genetic diagnosis services for Oncology, Pre&amp;Neonatal, Rare Diseases, and Health Check-ups and suggesting personalized treatment for longer and healthier lives. Established in 2013 as a GC company, GC Genome operates a CAP-accredited laboratory and places the utmost emphasis on R&amp;D. With steadfast partnerships established worldwide, GC Genome has shown impressive growth momentum, continually expanding our testing capacities.<\/p>\n<p><b>GC Genome Contacts (Media)<\/b><\/p>\n<p><span class=\"xn-person\">Sohee Kim<\/span><br \/><a href=\"mailto:shkim20@gccorp.com\" target=\"_blank\" rel=\"nofollow\">shkim20@gccorp.com<\/a><\/p>\n<p><span class=\"xn-person\">Yelin Jun<\/span><br \/><a href=\"mailto:yelin@gccorp.com\" target=\"_blank\" rel=\"nofollow\">yelin@gccorp.com<\/a><\/p>\n<p><span class=\"xn-person\">Yoonjae Na<\/span><br \/><a href=\"mailto:yjy6520@gccorp.com\" target=\"_blank\" rel=\"nofollow\">yjy6520@gccorp.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2833373\/GC_Genome_logo_final_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\">YONGIN, <span class=\"xn-location\">South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 27, 2025<\/span><\/span> \/PRNewswire\/ &#8212; GC Genome, a leading clinical genomics and liquid biopsy company, announced that its collaborative study with Professor Byeon, Jeong-Sik&#8217;s team at Asan Medical Center has been published in <i>The American Journal of Gastroenterology(AJG)<\/i>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>GC Genome applied its proprietary AI-based fragmentomics technology, used in its MCED test, ai-CANCERCH. This study demonstrates the potential for a convenient, alternative to colonoscopy and fecal based screening methods, while enabling early detection of colorectal cancer and advanced adenomas.<\/p>\n<p><b>Study Overview<\/b><\/p>\n<ul type=\"disc\">\n<li>A total of 1,677 individuals were enrolled, including: 302 with\u00a0CRC, 108 with AA<\/li>\n<li>1,267 with normal\u00a0colonoscopy as healthy or non-cancer controls<\/li>\n<\/ul>\n<p>The test analyzes cfDNA fragmentomic signatures using low-coverage whole-genome sequencing (Lc-WGS) combined with a proprietary AI algorithm, enabling highly sensitive detection of early-stage disease.<\/p>\n<p><b>Key Findings<\/b><\/p>\n<ul type=\"disc\">\n<li>CRC sensitivity: 90.4%<\/li>\n<li>Specificity in individuals with normal\u00a0colonoscopy: 94.7%<\/li>\n<li>Sensitivities by\u00a0CRC stage : 84.2% (stage I), 85.0% (stage II), 94.4% (stage III), and 100.0% (stage IV)<\/li>\n<li>Sensitivity for T1N0 lesions (eligible for\u00a0endoscopic resection): 90.0%<\/li>\n<li>Sensitivity for AA: 58.3%<\/li>\n<\/ul>\n<p>The results remained consistent regardless of: CRC locations (left vs. right colon), age of CRC patients(&lt;60 vs. \u226560), and AA locations<\/p>\n<p>These findings highlight the test&#8217;s potential as a reliable cfDNA-based blood test for CRC screening and early prevention.<\/p>\n<p>A GC Genome spokes person stated &#8220;Detecting colorectal cancer together with precancerous lesions represents a meaningful advance in prevention. With our fragmentomics technology now validated through publication in a leading gastroenterology journal, GC Genome will continue expanding global clinical collaborations and screening applications.&#8221;<\/p>\n<p><b>About ai-CANCERCH<\/b><\/p>\n<p>Launched in <span class=\"xn-chron\">September 2023<\/span>, ai-CANCERCH is an AI-based multi-cancer early detection(MCED) test powered by Lc-WGS. Using just 10 mL of blood, the test detects signals associated with multiple cancers. A major upgrade\u2014expanding from 6 detectable cancers to 10 cancers (colorectal, lung, esophageal, liver, ovarian, pancreatic, biliary, breast, gastric, and head-and-neck)\u2014is planned for <span class=\"xn-chron\">January 2026<\/span>.<\/p>\n<p><b>About GC Genome<\/b><\/p>\n<p>GC Genome is a leading diagnostics company that aims to connect the care and cure to the world by offering genetic diagnosis services for Oncology, Pre&amp;Neonatal, Rare Diseases, and Health Check-ups and suggesting personalized treatment for longer and healthier lives. Established in 2013 as a GC company, GC Genome operates a CAP-accredited laboratory and places the utmost emphasis on R&amp;D. With steadfast partnerships established worldwide, GC Genome has shown impressive growth momentum, continually expanding our testing capacities.<\/p>\n<p><b>GC Genome Contacts (Media)<\/b><\/p>\n<p><span class=\"xn-person\">Sohee Kim<\/span><br \/><a href=\"mailto:shkim20@gccorp.com\" target=\"_blank\" rel=\"nofollow\">shkim20@gccorp.com<\/a><\/p>\n<p><span class=\"xn-person\">Yelin Jun<\/span><br \/><a href=\"mailto:yelin@gccorp.com\" target=\"_blank\" rel=\"nofollow\">yelin@gccorp.com<\/a><\/p>\n<p><span class=\"xn-person\">Yoonjae Na<\/span><br \/><a href=\"mailto:yjy6520@gccorp.com\" target=\"_blank\" rel=\"nofollow\">yjy6520@gccorp.com<\/a><\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-39777","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/39777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39777"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/39777\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39777"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39777"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}